Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer

Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer

Blog Article

Pembrolizumab, an inhibitor target programmed death 1 (PD-1), was approved into the first line therapy in 1958 impala continental kit advanced non-small cell lung cancer (NSCLC).It was a milestone that immune checkpoints drugs have played an important role in the treatment system of NSCLC.The results of clinical trials revealed the superiority of PD-1/programmed death ligand 1 (PD-L1) inhibitors compared with chemotherapy in first-line, second-line and multidrug resistance phase therapy.Objective response rate (ORR) was up to 80% with pembrolizumab plus chemotherapy, and progression-free survival (PFS) with single pembrolizumab in first line was nearly 1 year (10.

3 months), the hazard ratio for death fell by 40%.Overall survival (OS) was more or less 1 year with single drug pembrolizumab, nivolumab and atezolizumab for second line therapy.PD-L1 expression was a predictor of PD-1/PD-L1 inhibitors.The positive rate of PD-L1 (more than 1%) in advanced NSCLC was about 60% with little difference between the tissue zury sis wigs chill types.

However, there was no gold standard test of PD-L1 expression.